Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
adebrelimab + cetuximab
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Adebrelimab + cetuximab is an investigational combination regimen consisting of a PD-L1 inhibitor and an EGFR inhibitor. Adebrelimab (also known as SHR-1316) is a humanized monoclonal antibody that targets programmed death-ligand 1 (PD-L1), acting as an immune checkpoint inhibitor to restore T-cell mediated anti-tumor activity. Cetuximab is a chimeric monoclonal antibody that targets the epidermal growth factor receptor (EGFR), inhibiting downstream signaling pathways involved in cell growth and survival. This combination, often administered alongside chemotherapy (such as FOLFOX6 or FOLFIRI), is being evaluated for the treatment of RAS/BRAF wild-type unresectable liver metastases from colorectal cancer. The goal of this triplet approach is to convert initially unresectable liver metastases into resectable ones, thereby improving the prognosis and overall survival of patients with metastatic colorectal cancer.
- Brand names
- Haihe
- Other names
- adebrelimab plus cetuximabSHR-1316 plus cetuximabSHR1316 plus cetuximabSHR 1316 plus cetuximab
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on adebrelimab + cetuximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on adebrelimab + cetuximab.